157 related articles for article (PubMed ID: 23739952)
41. Evaluation of effects of polymorphism for metabolic enzymes on pharmacokinetics of carvedilol by population pharmacokinetic analysis.
Takekuma Y; Takenaka T; Kiyokawa M; Yamazaki K; Okamoto H; Kitabatake A; Tsutsui H; Sugawara M
Biol Pharm Bull; 2007 Mar; 30(3):537-42. PubMed ID: 17329852
[TBL] [Abstract][Full Text] [Related]
42. Oxidation of R(+)- and S(-)-carvedilol by rat liver microsomes. Evidence for stereoselective oxidation and characterization of the cytochrome P450 isozymes involved.
Fujimaki M
Drug Metab Dispos; 1994; 22(5):700-8. PubMed ID: 7835220
[TBL] [Abstract][Full Text] [Related]
43. Optimized nanoemulsifying systems with enhanced bioavailability of carvedilol.
Singh B; Singh R; Bandyopadhyay S; Kapil R; Garg B
Colloids Surf B Biointerfaces; 2013 Jan; 101():465-74. PubMed ID: 23010056
[TBL] [Abstract][Full Text] [Related]
44. Mucoadhesive bilayer buccal tablet of carvedilol-loaded chitosan microspheres: in vitro, pharmacokinetic and pharmacodynamic investigations.
Yedurkar P; Dhiman MK; Petkar K; Sawant K
J Microencapsul; 2012; 29(2):126-37. PubMed ID: 22047549
[TBL] [Abstract][Full Text] [Related]
45. Pharmacokinetic profile of controlled-release carvedilol in patients with left ventricular dysfunction associated with chronic heart failure or after myocardial infarction.
Packer M; Lukas MA; Tenero DM; Baidoo CA; Greenberg BH;
Am J Cardiol; 2006 Oct; 98(7A):39L-45L. PubMed ID: 17023231
[TBL] [Abstract][Full Text] [Related]
46. Comparison of the pharmacokinetic properties of bisoprolol and carvedilol in healthy dogs.
Beddies G; Fox PR; Papich MD; Kanikanti VR; Krebber R; Keene BW
Am J Vet Res; 2008 Dec; 69(12):1659-63. PubMed ID: 19046015
[TBL] [Abstract][Full Text] [Related]
47. Analysis of carvedilol enantiomers in human plasma using chiral stationary phase column and liquid chromatography with tandem mass spectrometry.
Poggi JC; Da Silva FG; Coelho EB; Marques MP; Bertucci C; Lanchote VL
Chirality; 2012 Mar; 24(3):209-14. PubMed ID: 22271587
[TBL] [Abstract][Full Text] [Related]
48. Dose-effect and pharmacokinetic-pharmacodynamic relationships of the beta 1-adrenergic receptor blocking properties of various doses of carvedilol in healthy humans.
de Mey C; Breithaupt K; Schloos J; Neugebauer G; Palm D; Belz GG
Clin Pharmacol Ther; 1994 Mar; 55(3):329-37. PubMed ID: 7908256
[TBL] [Abstract][Full Text] [Related]
49. The Pharmacokinetic Interaction Study between Carvedilol and Bupropion in Rats.
Abrudan MB; Muntean DM; Gheldiu AM; Neag MA; Vlase L
Pharmacology; 2017; 99(3-4):139-143. PubMed ID: 28052289
[TBL] [Abstract][Full Text] [Related]
50. Enantioselective pharmacokinetics of carvedilol in human volunteers.
Phuong NT; Lee BJ; Choi JK; Kang JS; Kwon KI
Arch Pharm Res; 2004 Sep; 27(9):973-7. PubMed ID: 15473670
[TBL] [Abstract][Full Text] [Related]
51. The pharmacokinetics of carvedilol and its metabolites after single and multiple dose oral administration in patients with hypertension and renal insufficiency.
Gehr TW; Tenero DM; Boyle DA; Qian Y; Sica DA; Shusterman NH
Eur J Clin Pharmacol; 1999 Jun; 55(4):269-77. PubMed ID: 10424319
[TBL] [Abstract][Full Text] [Related]
52. In vitro permeation of carvedilol through porcine skin: effect of vehicles and penetration enhancers.
Gannu R; Vishnu YV; Kishan V; Rao YM
PDA J Pharm Sci Technol; 2008; 62(4):256-63. PubMed ID: 19174954
[TBL] [Abstract][Full Text] [Related]
53. Inhibitory Effect of Citalopram on the Pharmacokinetics of Carvedilol in Rats and in vitro Models.
Abrudan MB; Muntean DM; Popa DS; Gheldiu AM; Neag MA; Vlase L
Pharmacology; 2017; 100(5-6):301-307. PubMed ID: 28848215
[TBL] [Abstract][Full Text] [Related]
54. Stereoselective metabolism of carvedilol by the beta-naphthoflavone-inducible enzyme in human intestinal epithelial Caco-2 cells.
Ishida K; Honda M; Shimizu T; Taguchi M; Hashimoto Y
Biol Pharm Bull; 2007 Oct; 30(10):1930-3. PubMed ID: 17917264
[TBL] [Abstract][Full Text] [Related]
55. Measurement of carvedilol enantiomers in human plasma and urine using S-naproxen chloride for chiral derivatization.
Spahn H; Henke W; Langguth P; Schloos J; Mutschler E
Arch Pharm (Weinheim); 1990 Aug; 323(8):465-9. PubMed ID: 1980583
[TBL] [Abstract][Full Text] [Related]
56. Controlled-release carvedilol.
Carter NJ; Keating GM
Am J Cardiovasc Drugs; 2008; 8(4):271-82. PubMed ID: 18690761
[No Abstract] [Full Text] [Related]
57. Dose proportionality and pharmacokinetics of carvedilol sustained-release formulation: a single dose-ascending 10-sequence incomplete block study.
Kim YH; Choi HY; Noh YH; Lee SH; Lim HS; Kim C; Bae KS
Drug Des Devel Ther; 2015; 9():2911-8. PubMed ID: 26089641
[TBL] [Abstract][Full Text] [Related]
58. Formation of a carbamoyl glucuronide conjugate of carvedilol in vitro using dog and rat liver microsomes.
Schaefer WH
Drug Metab Dispos; 1992; 20(1):130-3. PubMed ID: 1346989
[No Abstract] [Full Text] [Related]
59. Exercise does not affect plasma concentrations of (R)- and (S)-carvedilol.
Stoschitzky K; Koshucharova G; Zweiker R; Lercher P; Maier R; Klein W; Zitta S; Gruber L; Lamprecht G; Lindner W
Cardiovasc Drugs Ther; 2002 Mar; 16(2):133-40. PubMed ID: 12090906
[TBL] [Abstract][Full Text] [Related]
60. Effect of Asparagus racemosus extract on transdermal delivery of carvedilol: a mechanistic study.
Sapra B; Jain S; Tiwary AK
AAPS PharmSciTech; 2009; 10(1):199-210. PubMed ID: 19238554
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
